Industry Focus

For several years, Procter & Gamble has been spinning off low-priority brands and cutting costs to streamline its business. But with little to show for those efforts, billionaire Nelson Peltz wants a seat at the table. Meanwhile, a slow summer blockbuster season is taking a major toll on theater operators.

Business development companies are undergoing a sea change as the asset class becomes more institutionalized.

Snap's quarterly update was... uninspiring. On this show, we talk about the updated user counts, ask some questions on engagement metrics, and run through the new financials.

Fracking has been the oil industry buzzword for years, here’s what the process actually means.

Scotts Miracle Gro could be the best marijuana stock to buy, while Illumina could be the best bet to capitalize on DNA-based medicine.

You might not be able to fire the coach or have a say in drafting new players, but there are ways to invest in professional sports.

Here's the differences between the major credit card processors, and how to evaluate them as investments.

We try and decode what's going on with Twitter's DAU/MAU numbers, and run through the figures on another banner quarter for the world's largest company.

Years after the downturn started, oil majors relent and believe $50 oil is the new reality. Are they right?

How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.  

We break down the latest developments in the consumer-retail sector, including Amazon earnings, the $1.4 billion Jimmy Choo buyout, and the turnaround prospects for Target. Get $25 off your first purchase at http://bombfell.com/fool.

Before you follow an advisor's advice on these topics, make sure you know the whole story.

New quarterly numbers from Alphabet and Facebook sent the stocks in different directions -- why did the Street love one set of estimate-beating numbers and not the other?

Fossil fuels may be critical today, but that fact is changing at an accelerated rate.

Hunting for new small cap stocks to watch? We've got you covered. In today's show, we discuss how NovoCure, Flexion Therapeutics, and Zogenix want to shake-up healthcare.

Michael Kors scoops up Jimmy Choo to keep pace with Coach, and Lululemon's back after a spring mishap, could its winning days continue? We hit these retail news items and check in on Chipotle's food-borne illness problems ahead of earnings.

For years after the financial crisis, bank earnings fluctuated wildly due to high loan losses, volatile markets, and elevated legal expenses. Fortunately, this trend seems to have come to an end, as the results from the second quarter demonstrate.  

Shopify and its founder Tobias Lütke have been Fool favorites for a long time -- on this episode we talk about how, despite the stock's crazy run over the past year, we're still interested in the e-commerce company. Thanks to Harry’s for supporting Motley Fool. Get your Free Trial Set – go to Harrys.com/fool

OPEC’s production cut compliance continues to drop, is this the end of its attempt to prop up oil prices?

After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being run by proven CEOs. Could experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too? Thanks to Slack for supporting Motley Fool. Learn more at slack.com.